Recon: AstraZeneca extends cancer drugs reach with EsoBiotec $1B purchase; Top 10 US drugs losing exclusivity this year
Welcome to Regulatory Reconnaissance, your regulatory news and intelligence briefing.In Focus: US
- Pfizer Has a New Playbook for Reviving Sales—and It’s Starting to Pay Off (The Wall Street Journal)
- At NIH, ‘everyone is on edge’ as they brace for deep cuts and more centralized control (STAT)
- Novartis is watching US reciprocal tariff policy 'very carefully', CEO says (Reuters)
- The top 10 drugs losing US exclusivity in 2025 (Fierce Pharma)
- Small vaccine maker names Operation Warp Speed leader as chairman, raises $110 million (STAT)
- These 12 Chinese companies are poised to transform CRISPR gene-editing (STAT)
- U.K. plan to require drugmakers to pay higher rebates draws criticism from industry group (STAT)
- Otsuka's Taiho buys Swiss startup Araris with three ADCs nearing the clinic (Endpoints)
- EU Pushes Faster Route For Innovative And Orphan Devices (MedTech Insight)
- Novo Nordisk membership in UK pharma body restored after suspension (Reuters)
- AstraZeneca boosts cancer therapies push with $1 billion EsoBiotec buy (Reuters)
- Purified T cell transplant lowers risk of immune reaction for blood cancer patients, study shows (STAT)
- Altimmune to study obesity drug in alcohol use disorder, following Eli Lilly (STAT)
- OPKO and Entera partner to develop obesity pill (Reuters)
- Stada plans to launch IPO as soon as Wednesday, sources say (Reuters)
- Incyte's skin disease drug fails to impress in late-stage studies (Reuters)
- Exclusive: KKR-Warburg Pincus group submit non-binding bid for Gerresheimer, sources say (Reuters)
- Curevo gets $110M for a shot against Shingrix, gets Moncef Slaoui and Tal Zaks on board (Endpoints)
- George Church spinout developing genomically recoded organisms cuts most employees (Endpoints)
- AstraZeneca spotlights first-in-human data for B7-H4-targeting ADC in endometrial cancer (Endpoints)
- HC Bioscience, a tRNA biotech backed by ARCH and Takeda, shuts down (Endpoints)
- Sutro slashes workforce in half, changes CEO and closes factory (Endpoints)
- New Stanford tool evaluates AI models on tasks that actually matter in health care (STAT)
- Q&A: How AI can fail people with disabilities (STAT)
- FDA adds hemodialysis devices to shortage list amid B. Braun disruption (MedTech Dive)
- Dr. Oz stresses need for faster Medicare coverage of new devices during confirmation hearing (MedTech Dive)
- Vicarious Surgical appoints Sarah Romano as CFO (MedTech Dive)
- Careology And Entia Partner To ‘Enhance’ Remote Monitoring For Patients With Cancer (MedTech Insight)
- Study: Nearly 30% Of Device Adverse Event Reports Don’t Meet Deadline (MedTech Insight)
- Dr. Oz pledges Medicare Advantage scrutiny: ‘There is a new sheriff in town’ (STAT)
- Howard Dean: Sympathy, not sanctimony, is the right response to vaccine fears (STAT)
- HIPAA can’t keep up with health care’s security crisis (STAT)
- US reports first outbreak of deadly H7N9 bird flu since 2017 (Reuters)
- ACI’s 21st Annual Paragraph IV Disputes (FDA Law Blog)
A story’s inclusion in Regulatory Recon does not imply endorsement by Regulatory Focus or RAPS.
